Literature DB >> 31077781

Oxygenation strategies for encapsulated islet and beta cell transplants.

Klearchos K Papas1, Hector De Leon2, Thomas M Suszynski3, Robert C Johnson2.   

Abstract

Human allogeneic islet transplantation (ITx) is emerging as a promising treatment option for qualified patients with type 1 diabetes. However, widespread clinical application of allogeneic ITx is hindered by two critical barriers: the need for systemic immunosuppression and the limited supply of human islet tissue. Biocompatible, retrievable immunoisolation devices containing glucose-responsive insulin-secreting tissue may address both critical barriers by enabling the more effective and efficient use of allogeneic islets without immunosuppression in the near-term, and ultimately the use of a cell source with a virtually unlimited supply, such as human stem cell-derived β-cells or xenogeneic (porcine) islets with minimal or no immunosuppression. However, even though encapsulation methods have been developed and immunoprotection has been successfully tested in small and large animal models and to a limited extent in proof-of-concept clinical studies, the effective use of encapsulation approaches to convincingly and consistently treat diabetes in humans has yet to be demonstrated. There is increasing consensus that inadequate oxygen supply is a major factor limiting their clinical translation and routine implementation. Poor oxygenation negatively affects cell viability and β-cell function, and the problem is exacerbated with the high-density seeding required for reasonably-sized clinical encapsulation devices. Approaches for enhanced oxygen delivery to encapsulated tissues in implantable devices are therefore being actively developed and tested. This review summarizes fundamental aspects of islet microarchitecture and β-cell physiology as well as encapsulation approaches highlighting the need for adequate oxygenation; it also evaluates existing and emerging approaches for enhanced oxygen delivery to encapsulation devices, particularly with the advent of β-cell sources from stem cells that may enable the large-scale application of this approach.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Devices; Diabetes; Encapsulation; Islet transplantation; Oxygen

Mesh:

Substances:

Year:  2019        PMID: 31077781     DOI: 10.1016/j.addr.2019.05.002

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  13 in total

1.  An Atmosphere-Breathing Refillable Biphasic Device for Cell Replacement Therapy.

Authors:  Duo An; Long-Hai Wang; Alexander Ulrich Ernst; Alan Chiu; Yen-Chun Lu; James Arthur Flanders; Ashim Kumar Datta; Minglin Ma
Journal:  Adv Mater       Date:  2019-11-11       Impact factor: 30.849

Review 2.  The Foundation for Engineering a Pancreatic Islet Niche.

Authors:  Smit N Patel; Clayton E Mathews; Rachel Chandler; Cherie L Stabler
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

3.  Oligomeric collagen as an encapsulation material for islet/β-cell replacement: effect of islet source, dose, implant site, and administration format.

Authors:  Clarissa Hernandez Stephens; Rachel A Morrison; Madeline McLaughlin; Kara Orr; Sarah A Tersey; J Catharine Scott-Moncrieff; Raghavendra G Mirmira; Robert V Considine; Sherry Voytik-Harbin
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-06-16       Impact factor: 4.310

4.  A nanofibrous encapsulation device for safe delivery of insulin-producing cells to treat type 1 diabetes.

Authors:  Xi Wang; Kristina G Maxwell; Kai Wang; Daniel T Bowers; James A Flanders; Wanjun Liu; Long-Hai Wang; Qingsheng Liu; Chengyang Liu; Ali Naji; Yong Wang; Bo Wang; Jing Chen; Alexander U Ernst; Juan M Melero-Martin; Jeffrey R Millman; Minglin Ma
Journal:  Sci Transl Med       Date:  2021-06-02       Impact factor: 17.956

5.  Organoid microphysiological system preserves pancreatic islet function within 3D matrix.

Authors:  S N Patel; M Ishahak; D Chaimov; A Velraj; D LaShoto; D W Hagan; P Buchwald; E A Phelps; A Agarwal; C L Stabler
Journal:  Sci Adv       Date:  2021-02-12       Impact factor: 14.136

6.  Optimal Time to Ship Human Islets Post Tissue Culture to Maximize Islet.

Authors:  Barbara J Olack; Michael Alexander; Carol J Swanson; Julie Kilburn; Nicole Corrales; Antonio Flores; Jennifer Heng; Jayagowri Arulmoli; Keiko Omori; Peter J Chlebeck; Laura Zitur; Mayra Salgado; Jonathan R T Lakey; Joyce C Niland
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

7.  A bioinspired scaffold for rapid oxygenation of cell encapsulation systems.

Authors:  Long-Hai Wang; Alexander Ulrich Ernst; Duo An; Ashim Kumar Datta; Boris Epel; Mrignayani Kotecha; Minglin Ma
Journal:  Nat Commun       Date:  2021-10-06       Impact factor: 14.919

Review 8.  Integration of nano- and biotechnology for beta-cell and islet transplantation in type-1 diabetes treatment.

Authors:  Andras Dinnyes; Andrea Schnur; Suchitra Muenthaisong; Peter Bartenstein; Charles-Thibault Burcez; Neal Burton; Clemens Cyran; Pierre Gianello; Elisabeth Kemter; Gabor Nemeth; Francesco Nicotra; Eszter Prepost; Yi Qiu; Laura Russo; Andras Wirth; Eckhard Wolf; Sibylle Ziegler; Julianna Kobolak
Journal:  Cell Prolif       Date:  2020-04-27       Impact factor: 6.831

9.  Generating low immunogenic pig pancreatic islet cell clusters for xenotransplantation.

Authors:  Marco Carvalho Oliveira; Emilio Valdivia; Murielle Verboom; Yuliia Yuzefovych; Hendrik Johannes Sake; Olena Pogozhykh; Heiner Niemann; Reinhard Schwinzer; Björn Petersen; Jochen Seissler; Rainer Blasczyk; Constança Figueiredo
Journal:  J Cell Mol Med       Date:  2020-03-25       Impact factor: 5.310

Review 10.  Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes.

Authors:  Debkalpa Goswami; Daniel A Domingo-Lopez; Niamh A Ward; Jeffrey R Millman; Garry P Duffy; Eimear B Dolan; Ellen T Roche
Journal:  Adv Sci (Weinh)       Date:  2021-06-21       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.